Abstract
Background DNA methylation of cytosines at CpG dinucleotides is a widespread epigenetic mark; but genome-wide variation has been relatively unexplored due to the limited representation of variable CpGs on commercial high-throughput arrays.
Objective To explore this hidden portion of the epigenome, we combined whole-genome bisulfite sequencing (WGBS) with in silico evidence of gene regulatory regions to design a custom array of high-value CpGs. We focused these studies in airway epithelial cells from children with and without allergic asthma because these cells mediate the effects of inhaled microbes, pollution, and allergens on asthma and allergic disease risk.
Methods We identified differentially methylated regions (DMRs) from WGBS in nasal epithelial cell (NEC) DNA from 39 children with and without allergic asthma of both European and African ancestries. We selected CpGs from DMRs, previous allergy or asthma Epigenome-Wide Association Studies (EWAS), or Genome-Wide Association Study (GWAS) loci, and overlapped them with functional annotations for inclusion on a custom Asthma&Allergy array. Using both the Custom and EPIC arrays, we performed EWAS of allergic sensitization (AS) in NEC DNA from children in the URECA birth cohort and using the Custom array in the INSPIRE birth cohort. We assigned each CpG on the arrays to its nearest gene and its promotor capture Hi-C interacting gene and performed expression quantitative trait methylation (eQTM) studies for both sets of genes.
Results Custom array CpGs were enriched for intermediate methylation (IM) levels compared to EPIC CpGs. IM CpGs were further enriched among those associated with AS and for eQTMs on both arrays.
Conclusions Our study revealed signature features of high-value CpGs and evidence for epigenetic regulation of genes at AS EWAS loci that are robust to race/ethnicity, ascertainment, age, and geography.
Clinical Implications These studies identified allergic sensitization-associated differentially methylated CpGs and their target genes in airway epithelium, providing potential epigenetic mechanisms in the development of allergic diseases and suggesting novel drug targets.
Capsule Summary This study of previously unexplored regions of the airway epithelial methylome revealed novel epigenetic mechanisms regulating genes previously implicated in the pathogenesis of asthma and allergic diseases.
Competing Interest Statement
L.B.B. reports personal fees from GlaxoSmithKline Genentech/Novartis, Merck, DBV Technologies, Teva, Boehringer Ingelheim, AstraZeneca, WebMD/Medscape, Sanofi/Regeneron, Vectura, Circassia, Elsevier, Kinaset, and Vertex outside the submitted work. G.T.O. has received consulting fees from Dicerna and Menarini unrelated to this work. R.A.W. has received grants from Aimmune, Astellas, DBV, Genentech, Novartis, Regeneron, and Sanofi. K.C.B. is employed by Tempus Labs. M.C.A. has received consulting fees from Regeneron outside the submitted work. D.J.J. reports grants and personal fees from GlaxoSmithKline and Regeneron and personal fees from Pfizer, Sanofi, AstraZeneca, and Vifor Pharma, outside the submitted work. J.E.G. is a paid consultant for AstraZeneca and Meissa Vaccines Inc. and has stock options in Meissa Vaccines Inc.
Funding Statement
Research reported in this publication was supported by the Environmental influences on Child Health Outcomes (ECHO) program, Office of The Director, National Institutes of Health, under Award Numbers U2COD023375 (Coordinating Center), U24OD023382 (Data Analysis Center), U24OD023319 (PRO Core), UH3 OD023282 (COAST, INSPIRE, URECA) and UH3 OD023288 (VCSIP); and grants UM1 AI114271, UM1 AI160040, U19 AI62310, U19 AI095227, UL1 TR002243 P51 OD011092 and R01 HL104608.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Boards of Boston University, Columbia University, Johns Hopkins, and Washington University (URECA), University of Wisconsin-Madison (COAST), Vanderbilt University School of Medicine (INSPIRE), and Oregon Health & Science University, PeaceHealth Southwest Medical Center, Wishard or Indiana University Hospitals (VCSIP) all gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Grant Support: Research reported in this publication was supported by the Environmental influences on Child Health Outcomes (ECHO) program, Office of The Director, National Institutes of Health, under Award Numbers U2COD023375 (Coordinating Center), U24OD023382 (Data Analysis Center), U24OD023319 (PRO Core), UH3 OD023282 (COAST, INSPIRE, URECA) and UH3 OD023288 (VCSIP); and grants UM1 AI114271, UM1 AI160040, U19 AI62310, U19 AI095227, UL1 TR002243 P51 OD011092 and R01 HL104608.
Disclosures: L.B.B. reports personal fees from GlaxoSmithKline Genentech/Novartis, Merck, DBV Technologies, Teva, Boehringer Ingelheim, AstraZeneca, WebMD/Medscape, Sanofi/Regeneron, Vectura, Circassia, Elsevier, Kinaset, and Vertex outside the submitted work. G.T.O. has received consulting fees from Dicerna and Menarini unrelated to this work. R.A.W. has received grants from Aimmune, Astellas, DBV, Genentech, Novartis, Regeneron, and Sanofi. K.C.B. is employed by Tempus Labs. M.C.A. has received consulting fees from Regeneron outside the submitted work. D.J.J. reports grants and personal fees from GlaxoSmithKline and Regeneron and personal fees from Pfizer, Sanofi, AstraZeneca, and Vifor Pharma, outside the submitted work. J.E.G. is a paid consultant for AstraZeneca and Meissa Vaccines Inc. and has stock options in Meissa Vaccines Inc.
Some of the supplementary information has now been moved to the main text, but there are no significant differences between this version and the previously posted version.
Data Availability
All data produced are currently being made available at GEO and dbGaP.
Abbreviations
- AS
- allergic sensitization
- DMC
- differentially methylated CpG
- DMR
- differentially methylated region
- eQTM
- expression quantitative trait methylation
- EWAS
- epigenome-wide association study
- FET
- fisher exact test
- GWAS
- genome-wide association study
- IM
- intermediate methylation
- LF
- latent factors
- NEC
- nasal epithelial cells
- PCA
- principal components analysis
- SPT
- skin prick test
- WGBS
- whole-genome bisulfite sequencing
